Articles

Today marks World Sight Day, an annual day of awareness intended to focus global attention on blindness and vision impairment. Coordinated by the International Agency for the Prevention of Blindness, this year’s call is for everyone to “Love Your Eyes.”

Eye care industry takes action on World Sight Day to preserve vision worldwide

A review of studies, presentations and discussions at ASRS 2021 in San Antonio, Texas.

Roundup of findings reported at ASRS 39th Annual Scientific Meeting

Videos

Ankur Shah, MD, discusses key highlights of his presentation titled "YUTIQ CALM: a real-world registry study of the fluocinolone acetonide intravitreal implant 0.18 mg in chronic non-infectious posterior uveitis," during ASRS 2021. 

Dissecting real-world registry study of YUTIQ for chronic non-infectious posterior uveitis

Paul Hallen discusses the Retina Industry Insights panel at the Ophthalmology Innovation Summit in San Antonio, Texas.

Discussing retina industry insights at Ophthalmology Innovation Summit

Lynda Charters Enoch started her early “eye life” at the Schepens Eye Research Institute, Boston, which ultimately culminated in her current position as an Editor of 

The FDA approved Ocular Therapeutix Inc.’s Supplemental New Drug Application (sNDA) that further extends Dextenza’s (dexamethasone ophthalmic insert) 0.4 mg indications, the company announced Monday.

FDA approves Dextenza for third indication: Ocular itching from allergic conjunctivitis

During the American Society of Retina Specialists 2021 annual meeting, David Boyer, MD, told attendees that pegcetacoplan used to treat geographic atrophy proved to be well tolerated by patients in the phase 3 DERBY and OAKS studies.

OAKS and DERBY studies demonstrate efficacy of pegcetacoplan for Geographic Atrophy

In a presentation at the American Society of Retina Specialists 2021 annual meeting, Arshad Khanani, MD, MA, noted that investigators achieved results similar to those in patients treated with monthly ranibizumab injections for neovascular age-related macular degeneration. 

Study details Port Delivery System with ranibizumab in nAMD

The development-stage biotechnology company Omega Therapeutics is teaming up with Stanford University to investigate therapies for ocular diseases via control of specific ocular disease genes.

Omega Therapeutics announces collaboration with Stanford University School of Medicine

W. Lloyd Clark discusses his presentation at ASRS 2021, "Impact of Nonperfusion and Leakage Areas on Diabetic Macular Edema/Vision-Threatening Complications in Nonproliferative Diabetic Retinopathy (NPDR)."

PANOROMA elucidates effects of nonperfusion, leakage areas on DME, complications in NPDR

On October 14, we celebrate World Sight Day by pledging to receive annual eye exams, preventing or slowing vision loss, and showing love for our eyes.

Omega Therapeutics announces collaboration with Stanford University School of Medicine

PANOROMA elucidates effects of nonperfusion, leakage areas on DME, complications in NPDR

Celebrating World Sight Day 2021: How we #LoveYourEyes